Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EDAP TMS ( (EDAP) ) has shared an update.
On February 10, 2026, EDAP TMS director Glen French resigned from the Board of Directors and its audit, compensation and nominations committees, with the company stating his departure did not stem from any dispute with management or the board. The company announced on February 12, 2026, that David Horn, a seasoned healthcare finance and medical device executive, was appointed to the board effective February 11, 2026, and will serve on the audit and nominations committees, with his appointment to be put to a shareholder vote at the next annual general meeting.
Horn, currently President and Chief Financial Officer of Seer, Inc. and formerly a long-time Morgan Stanley managing director in healthcare investment banking, brings deep capital markets and strategic growth expertise that EDAP’s leadership says will support the company’s next phase of expansion. His independent status, lack of related-party ties and alignment with EDAP’s director compensation policy underscore a governance-focused transition aimed at reinforcing the board’s financial and industry capabilities as the company pursues growth in minimally invasive ultrasound therapies.
The most recent analyst rating on (EDAP) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.
Spark’s Take on EDAP Stock
According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow), despite strong technical momentum and encouraging earnings-call fundamentals around accelerating HIFU growth and maintained guidance. Valuation is neutral-to-weak due to negative earnings and no dividend support.
To see Spark’s full report on EDAP stock, click here.
More about EDAP TMS
EDAP TMS S.A., listed on Nasdaq as EDAP, is a global leader in therapeutic ultrasound and robotic energy-based therapies, developing, manufacturing, promoting and distributing minimally invasive medical devices worldwide. Its flagship product, Focal One, is a leading prostate focal therapy platform controlled by urologists, with potential applications beyond prostate cancer as the company targets broader clinical indications.
Average Trading Volume: 70,188
Technical Sentiment Signal: Buy
Current Market Cap: $172M
For an in-depth examination of EDAP stock, go to TipRanks’ Overview page.